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Abstract
Junı ´n virus (JUNV), an arenavirus, is the causative agent of Argentine hemorrhagic fever, an infectious human disease with
15–30% case fatality. The pathogenesis of AHF is still not well understood. Elevated levels of interferon and cytokines are
reported in AHF patients, which might be correlated to the severity of the disease. However the innate immune response to
JUNV infection has not been well evaluated. Previous studies have suggested that the virulent strain of JUNV does not
induce IFN in human macrophages and monocytes, whereas the attenuated strain of JUNV was found to induce IFN
response in murine macrophages via the TLR-2 signaling pathway. In this study, we investigated the interaction between
JUNV and IFN pathway in human epithelial cells highly permissive to JUNV infection. We have determined the expression
pattern of interferon-stimulated genes (ISGs) and IFN-b at both mRNA and protein levels during JUNV infection. Our results
clearly indicate that JUNV infection activates the type I IFN response. STAT1 phosphorylation, a downstream marker of
activation of IFN signaling pathway, was readily detected in JUNV infected IFN-competent cells. Our studies also
demonstrated for the first time that RIG-I was required for IFN production during JUNV infection. IFN activation was
detected during infection by either the virulent or attenuated vaccine strain of JUNV. Curiously, both virus strains were
relatively insensitive to human IFN treatment. Our studies collectively indicated that JUNV infection could induce host type I
IFN response and provided new insights into the interaction between JUNV and host innate immune system, which might
be important in future studies on vaccine development and antiviral treatment.
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Introduction
Arenaviruses are enveloped viruses with a bi-segmented negative
strand RNA genome [1]. Each genomic RNA segment, the L (ca.
7.3 kb) and S (ca. 3.5 kb) segments, uses an ambisense coding
strategy to direct the synthesis of two proteins in opposite
orientations from two open reading frames, which are separated
by a non-coding intergenic region (IGR) that acts as a transcription
termination signal for the virus polymerase [2,3]. The viral S
segment RNA encodes the viral glycoprotein precursor (GPC) and
the nucleoprotein (NP). GPC is post-translationally cleaved by the
cellular site 1 protease (S1P) to yield two glycoproteins, GP1 and
GP2, which form the viral spikes in the mature virion crucial for
receptor recognition and virus entry [4–6]. The L segment RNA
encodes the viral RNA dependent RNA polymerase (RdRp, or L
polymerase) [7], and the small (ca. 11 kDa) RING finger protein Z,
the latter representing arenavirus counterpart of the matrix protein
found in many other negative strand RNA viruses [8–10].
The Arenaviridae family includes several important human
pathogens [1,11]. Viruses often chronically infect their natural
rodent hosts worldwide [1]. Infection in humans occurs usually
through mucosal exposure to aerosols or by direct contact of
abraded skin with infectious materials and may result in severe
diseases such as hemorrhagic fever (HF). The Old World (OW)
Lassa virus (LASV) and several New World (NW) arenaviruses,
including Junı ´n virus (JUNV), pose a serious public health problem
within their endemic regions [1,11–13]. JUNV, an agent handled
mandatorily in a high-containment biosafety level 4 facility, causes
Argentine hemorrhagic fever (AHF), a highly infectious human
disease with 15–30% case fatality [13–16]. Despite extensive
studies in the past, the pathogenesis of HF arenaviruses remains
largely uncharacterized.
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response that enables the host to effectively fight against the
intruding pathogen [17,18]. Some of the potent host antiviral
responses depend on the production of interferons (IFNs),
including type I IFN (IFN-a and IFN-b) and type II IFN (IFN-
c) [19]. Induction of type I IFN is a critical event in the
establishment of the antiviral immune response, which results in
the reduction of viral spread and subsequent mobilization of
adaptive immune responses. During RNA virus infection, IFN
response in sentinel cells is initiated by pattern recognition
receptors (PRRs) that preferentially recognize viral RNAs typically
containing double-stranded RNA structures or 59 triphosphate
termini. Members of the PRR family include cell transmembrane
Toll-like receptors (TLRs) (TLR3, TLR7, TLR9), and cytoplasmic
RIG-I-like receptors (RLH), RIG-1 and MDA5 [20–24]. The
ubiquitous RIG-I and MDA5 are the primary PRRs that induce
IFN production by activation of Interferon Regulatory Factor 3
(IRF3) via the downstream Mitochondrial Antiviral Signaling
protein (MAVS, a.k.a IPS-1/VISA/Cardiff) [22,23]. Subsequent-
ly, newly synthesized IFNs signal through IFN receptor/JAK/
STAT pathway to induce the expression of a spectrum of IFN-
stimulated genes (ISG). Ultimately, different ISGs execute their
antiviral activities in a collaborative manner by targeting various
steps of virus replication [25]. Because of the potent antiviral
activities mediated by type I IFN, many viruses have evolved
strategies to target the RLH-MAVS pathway to evade the host
antiviral response [17,19].
High levels of IFN-a (2000 U/ml–64,000 U/ml) and other
cytokines are frequently measured in serum of AHF patients
[14,26–30]. High levels of IFN also co-exist with high viremia and
severe/fatal diseases [14,27]. One study has reported that a
virulent strain of JUNV does not induce detectable IFN
production in human macrophages [31], whereas another study
has shown that an attenuated JUNV can activate IFN response in
murine macrophages via TLR2 recognition of viral GP protein
[32]. The NP protein of JUNV, similar to NPs derived from many
other arenaviruses, has been found to exert an anti-IFN activity in
cell-based reporter gene assays [33–35]. However, the interplay
between JUNV and host IFN pathway in the context of virus-
infected cells has not been well investigated. Likewise, it is
unknown whether pathogenic and non-pathogenic strains of
JUNV induce different host innate immune responses. In the
present study, we have examined the interaction between JUNV
and type I IFN pathway in JUNV-infected human cells. We
provide evidence that non-monocyte/macrophage derived human
cells efficiently recognized JUNV during the early stages of
infection, which resulted in a potent RIG-I-dependent type I IFN
response that nonetheless had a very limited effect on JUNV
multiplication.
Materials and Methods
Viruses
The Romero and Candid#1 strains of JUNV were obtained
from Drs. Thomas G. Ksiazek (Centers for Disease Control and
Prevention, Atlanta, GA) and Robert Tesh (The World Reference
Center for Emerging Viruses and Arboviruses (WRCEVA),
University of Texas Medical Branch, Galveston, TX), respectively.
Virus stocks were propagated on Vero cells (American Tissue
Culture Collection, Manassas, VA), followed by filtration through
filters (0.45 mm pore size) to remove cell debris and purification
with Ultra 100K Filters Devices (Ultralcel 100K, molecular weight
cutoff 100,000, Amicon, Millipore) to remove cellular factors that
might mediate innate immune response. All work with the
pathogenic Romero strain JUNV was performed in the University
of Texas Medical Branch BSL 4 facilities (Robert E. Shope
Laboratory or the Galveston National Laboratory) in accordance
with institutional health and safety guidelines and federal
regulations as described previously [36,37].
Quantitative real-time RT-PCR (qRT-PCR)
cDNA synthesis and PCR amplification were performed with
iScript cDNA Synthesis Kit and iQ SYBR Green Supermix (Bio-
Rad, CA) according to the manufacturer’s instructions. Real-time
PCR was performed on CFX96 Real-Time PCR Detection
System (Bio-Rad, CA). Ct values were normalized to the average
Ct values of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and actin b (ACTB) housekeeping genes. Primers were designed
from target mRNA sequences obtained through NetAffx Analysis
Center (Affymetrix, Santa Clara, CA) using NCBI/Primer-
BLAST. The sequences of the primers used in qRT-PCR will
be available upon request. DDCt based fold-change calculations
and statistical analysis (Student’s t-test) of quantitative real-time
RT-PCR data were performed at the RT
2 Profiler
TM PCR Array
Data Analysis Web Portal (http://www.sabiosciences.com/pcr/
arrayanalysis.php).
Quantification of human IFN-b protein in cell culture
supernatants
Concentration of human IFN-b was measured by sandwich
ELISA method using VeriKine
TM Human IFN-Beta ELISA Kit
(PBL Interferon Source, NJ) according to the manufacturer’s
instruction.
Preparation of cytoplasmic (CE) and nuclear extracts (NE)
A549 cells were scraped and subjected to hypotonic buffer/
detergent lysis [38]. The supernatant (CE) was saved and the
nuclear extract (NE) was purified by centrifugation through a
sucrose cushion followed by extraction in Buffer C (50 mM
HEPES, pH 7.9, 10% glycerol, 400 mM KCl, 1 mM EDTA,
1 mM EGTA, 1 mM DTT and 0.1 mM PMSF) with protease
inhibitor cocktail (Sigma Aldrich, St. Louis, MO). Protein
concentration was estimated by Coomassie Brilliant Blue staining
Author Summary
Junı ´n virus (JUNV), which is endemic to the Argentinean
Pampas region, is the causative agent of Argentine
hemorrhagic fever (AHF), a severe illness with hemorrhagic
and neurological manifestations and with a case fatality of
15–30%. Clinical studies demonstrate that elevated levels
of interferon and cytokines are produced in AHF patients,
which might be correlated to the severity of disease.
However it remains unclear, especially during virus
infection, how human cells can sense virus infection and
respond by activation of IFN pathway. Our studies clearly
demonstrated that JUNV infection could activate type I IFN
response in human cells. IFN pathway activation occurred
in cells infected with either virulent strain or attenuated
vaccine strain of JUNV. Our data also revealed for the first
time that RIG-I was required for type I IFN production
during virus infection in human cells. Interestingly, both
strains of JUNV were relatively insensitive to human IFN
treatment, which might have implications for the role of
the IFN on virus infection in vivo. Overall, these results
indicate that JUNV infection could induce host IFN
response and provide new insights into JUNV and host
interaction as well as the mechanism underlying AHF.
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further subjected to quantitative proteomic analysis as described in
Text S1 and Table S1.
Virus sensitivity to IFN treatment
Vero cells were seeded into 96-well plates for 24 h and treated
with various concentrations of IFN-a-2b (Intron A, Schering
Corporation, NJ), IFN-b1a (Sigma-Aldrich, MO) (125, 250, 500,
1000 and 2000 U/ml) or IFN-c (Sigma-Aldrich, MO) (125, 250,
500 and 1000 U/ml) for 8 h. Cells were infected with Candid#1
or Romero strains of viruses at a multiplication of infection (MOI)
of 0.1 PFU/cell or mock-infected. Supernatants were collected at
2 days post infection (p.i.) and virus titers were determined by
plaque assay on Vero cells. MTT-based viability assay was
performed to ensure that the reduction of virus titer was associated
with the antiviral effect but not with the potential cytotoxicity of
IFNs. Due to the severe cytotoxicity caused by IFN-c treatment at
2000 U/ml, virus infection was not performed at this condition.
Knockdown of gene expression via siRNA
ON-TARGET plus SMART pool siRNA targeting human
DDX58 (RIG-I), IRF3 or Non-targeting Pool (Thermo Fisher
Scientific Inc, Pittsburgh, PA) were transfected into A549 cells by
electroporation using Amaxa Cell Line Nucleofector Kit T (Lonza
Walkersville, Inc., MD) according to the manufacturer’s protocol.
At 24 h post transfection (p.t.), cells were seeded into 12-well
plates. At 48 h p.t. cells were mock-infected or infected with
Candid#1 virus at an MOI of 1 PFU/cell and incubated for
another 24 h. Total RNA was extracted as described earlier.
Protein lysate was prepared in parallel in 16SDS-PAGE loading
buffer and subjected to Western blotting analysis.
Western blotting (WB) and antibodies
Protein samples were resolved on 4–20% SDS-PAGE gel and
transferred to PVDF membranes using Mini Trans-Blot Electro-
phoretic Transfer Cell apparatus (Bio-Rad, CA). The membranes
were incubated with primary antibodies overnight at 4uC and then
with appropriate secondary antibodies for 1 h at room tempera-
ture. Proteins were visualized with ECL Western Blotting
Detection Reagents (GE, NJ) according to the manufacturer’s
instruction. Primary antibodies used for western blotting analysis
were rabbit anti-phosphorylated STAT1 antibody (#9171, Cell
Signaling), mouse anti-STAT1 antibody (WH0006772M1, Sig-
ma), rabbit polyclonal anti-RIG-I antibody (AP1900a, Abgent
Inc., San Diego, CA), rabbit anti-IRF 3 antibody (ab76409,
Abcam), and goat anti-human b actin antibody (sc-1616, Santa
Cruz Biotechnology). Secondary antibodies used were HRP-
conjugated goat anti-rabbit IgG (#7074, Cell Signaling), HRP-
conjugated Goat anti-mouse IgG (115-035-146, Jackson Immu-
nology) and HRP-conjugated donkey anti-goat IgG (sc-2020,
Santa Cruz).
IFN reporter assay
Vero cells grown on 12-well plates were co-transfected with IFN
reporter plasmid pISRE-luc and renillar luciferase expression
vector pRL-SV40 with Lipofectamine 2000 (Invitrogen). At 24 h
p.t., cells were mock-infected or infected with Candid#1 JUNV at
an MOI of 1 for 24 h. Cells were treated with IFN-a (1000 IU/ml)
for 6 h. Cell lysates were prepared and subjected to dual luciferase
reporter assay (Dual-Luciferase reporter assay system, Promega)
according to the manufacturer’s protocol. The ISRE-driven firefly
luciferase expression levels were normalized to those of renillar
luciferase. All experiments were performed in triplicates.
Venezuelan equine encephalitis virus (VEEV) TC83-GFP
super-infection assay
A549 or Vero cells were infected or mock-infected by
Candid#1 JUNV (MOI of 1.0) for 24 h. Then cells were super-
infected with VEEV TC83-GFP virus at an MOI of 0.1. At
different time points p.i., media from TC83-GFP virus infected
cells were harvested and subjected to plaque assay to determine
TC83-GFP virus titers in BHK cells. TC83-GFP virus infection
resulted in plaque formation in BHK cells at 48 h p.i. For JUNV
infection, plaque formation required virus infection for 7 to 8 days
in Vero cells. To rule out a possibility that JUNV alone could also
form plaques in BHK cells at 48 h p.i, we performed plaque assay
in parallel using media collected from cells infected with
Candid#1 JUNV alone in super-infection experiments. It was
confirmed that no plaque was formed in BHK cells at 48 h when
supernatants from cells infected by Candid#1 JUNV alone were
tested. As indicated, TC-83 GFP virus-driven GFP expression in
infected cells was also assessed by fluorescence microscopy at 24 h
p.i.
Results
Effect of infection with the non-pathogenic Candid#1
strain of JUNV on activation of the type I IFN pathway
To investigate the interaction between JUNV infection and the
type I IFN pathway, we used a human lung epithelial cell line
(A549) that has been used extensively in studies of arenavirus
infections [34,35] and likely recreates the situation associated with
aerosol transmission of JUNV [1,16]. In our initial experiments,
we used the vaccine strain Candid#1 JUNV, which can be studied
in BSL2 laboratories. A549 (IFN-competent) and Vero (IFN-
deficient) cells were infected with Candid#1 JUNV (MOI=1) and
analyzed for the expression of ISGs at 24 h p.i.. Candid#1 JUNV
infection induced ISG15 protein expression in A549 but not in
Vero cells (Figure 1A). The level of STAT1 protein, an ISG,
increased noticeably in infected A549 cells but not in Vero cells.
Interestingly, phosphorylation of STAT1 protein, a hallmark event
of IFN signaling, was evident in Candid#1 JUNV-infected A549,
but not in Vero cells (Figure 1A), suggesting that the downstream
IFN signaling pathway was activated and responsible for STAT1
phosphorylation.
To investigate the effect of virus infection on type I IFN
signaling, Vero cells were infected with Candid#1 JUNV for 24 h
and then treated with 1000 u/ml of IFN-a for 1 h. IFN treatment
led to STAT1 phosphorylation that was not affected by infection
with Candid#1 strain of JUNV (Figure 1A) in Vero cells. At this
time point, ISG15 protein expression was still too early to be
detected as expected. Similarly, Candid#1 JUNV infection did
not affect IFN-a induced expression of an ISRE-dependent
reporter gene (pISRE-luc) in transfected Vero cells (Figure 1B).
These findings indicated that Candid#1 JUNV infection has no
detectable impact on type I IFN signaling.
Early activation of the IFN-b promoter involves the activation
and nuclear translocation of IRF3, which is critical for type I IFN
response. Our finding that the IFN pathway was activated during
Candid#1 JUNV infection led us to further investigate nuclear
translocation of the endogenous IRF3 in infected cells. Our initial
studies using immunofluorescence microscopy did not show
significant levels of IRF3 translocation into nucleus in Candid#1
1 JUNV-infected cells, whereas IRF3 nuclear translocation was
readily detected in cells transfected with poly (IC) (data not shown).
We reasoned that this might reflect a low level of IRF3 activation
during virus infection, which might be difficult to discern by
immunofluorescence staining. Therefore, we examined IRF3
Activation of IFN Pathway by Junı ´n Virus
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infected cells by a highly specific stable isotopic dilution (SID)-
selected reaction monitoring (SRM)-mass spectrometry analysis
[38–40]. Cytoplasmic and nuclear extracts were prepared from
Candid#1 JUNV-infected A549 cells at different h p.i., followed
by measuring IRF3 protein levels in each subcellular fraction by
SID-SRM. This analysis revealed that a low level of IRF3 nuclear
translocation could be first detected at 6 h p.i. that peaked at 24 h
p.i. and was maintained elevated at 48 h p.i. (Figure 1C). The
percentage of total IRF3 translocated into the nucleus was 2.4%
and 4.8% at 6 and 24 h p.i., respectively. In comparison, only
0.71% and 1.5% of IRF3 was detected in nuclear fractions of
mock-infected cells at 6 and 24 h p.i., respectively. In a control
experiment, IRF3 nuclear translocation was readily detected in
cells transfected with poly (IC) (Figure S1). These results indicated
that moderate levels of nuclear translocation of endogenous IRF3
were induced during early stage of Candid#1 JUNV infection,
which likely contributed to type I IFN production and signaling
(Figure 1A).
IFN production during Candid#1 JUNV infection
We performed ELISA to directly measure the production of
IFN-b protein in tissue culture supernatant (TCS) from Candid#1
JUNV infected A549 cells. At 24 h p.i., Candid#1 JUNV
infection induced 701 pg/ml of IFN-b production in TCS, while
poly (IC) transfection by Lipofectamine 2000 resulted in a lower
level (16 pg/ml) of IFN production (Figure 2A). To identify the
biological potency of type I IFN production in Candid#1 JUNV
infected cells, we examined whether these A549 cells were resistant
to super-infection with the IFN sensitive VEEV TC83-GFP virus
Figure 1. Activation of IFN pathway by Candid#1 JUNV infection. (A) Vero and A549 cells were mock-infected or infected (MOI of 1) with
Candid#1 JUNV for 24 h and then mock-treated or treated with IFN-a (1000 IU/ml) for 1 h. Cell lysates were prepared and subjected to western
blotting analysis for phosphorylated STAT1 (p-STAT1), STAT1 protein (STAT1), ISG15 (ISG15), virus NP protein (NP) and human b-actin (actin). (B) Vero
cells were co-transfected with an IFN responsive IRES reporter plasmid pISRE-luc (expressing firefly luciferase) together with a plasmid constitutively
expressing the Renilla luciferase (RL) reporter gene under the Simian Virus 40 promoter (pRL-SV40). After 24 h of transfection, cells were infected with
Candid#1 JUNV (Candid) or mock infected (mock) for 24 h followed by mock- (IFN2) or IFN-a treatment (1000 IU/ml) (IFN+) for 6 hr. Cells lysates
were prepared and subjected to dual luciferase assay. The ISRE-driven firefly luciferase activity was normalized to the RL activity. Data shown are the
mean of three independent experiments (error bar, S.D.). (C) A549 cells were mock infected (mock) or infected with Candid#1 JUNV (Candid). At
various time points as indicated, cytoplasmic extract and nuclear extract were prepared for measurement of IRF3 protein level in cytoplasm and
nuclear fractions by SID-SRM analysis.
doi:10.1371/journal.pntd.0001659.g001
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JUNV-infected Vero cells (IFN-deficient) to super-infection with
VEEV TC83-GFP. VEEV-TC83 virus titers were determined by
plaque assay in BHK cells as reported [42]. VEEV-TC83 grew to
similar titers in both mock- and Candid#1 JUNV-infected Vero
cells (Figure 2B, left panel). In contrast, VEEV-TC83 virus titers
were reduced by more than 2.5- and 3.5-log in Candid#1 JUNV-
infected A549 cells at 24 and 48 h p.i., respectively (Figure 2B,
right panel). This result suggested that A549 cells became resistant
to other RNA virus infection after Candid#1 JUNV infection.
We also monitored VEEV virus replication in mock- and
Candid#1JUNV-infected Vero and A549 cells by assessing the
VEEV TC83 virus-driven GFP expression level. Consistent with
the results of VEEV TC83-GFP infectious progeny production,
replication of VEEV was severely affected in Candid#1 JUNV-
infected A549, but not in Vero cells (Figure 2C). In Vero cells,
similar numbers of GFP positive cells were identified in mock-
infected sample (205 counts) and Candid#1 JUNV-infected
sample (190 counts) (Figure 2C). Whereas in A549 cells, the
numbers of GFP positive cells were remarkably different between
mock-infected sample (75 counts) and Candid#1 JUNV-infected
sample (2 counts).
Effect of infection with the pathogenic Romero strain of
JUNV on activation of the IFN pathway
In an effort to understand the mechanisms underlying the
attenuation of Candid#1 vaccine strain of JUNV, we compared
the effect of virus infection on activation of type I IFN pathway
between the non-pathogenic (Candid#1) and pathogenic (Ro-
mero) strains of JUNV in A549 cells. These studies were
performed at the BSL-4 facilities at UTMB. Both Candid#1
and Romero virus strains induced noticeable levels of IFN-b and
ISG15 mRNA expression in A549 cells as determined by real-time
qRT-PCR (Figure 3A). IFN-b mRNA expression increased by 31-
fold and 29-fold in Romero JUNV infected cells at days 1 and 2
p.i., respectively, meanwhile ISG15 mRNA was upregulated by
45-fold and 62-fold in the same samples. Candid#1 JUNV-
infected cells expressed higher levels of IFN-b and ISG15 mRNAs
than Romero JUNV-infected cells (Figure 3A). We also performed
Western blotting analysis to determine the protein levels of ISGs
Figure 2. IFN induction in Candid#1 JUNV-infected cells. (A) A549 cells were mock-infected (mock) or Candid#1 JUNV infected (Candid) (MOI
of 1) for 24 h. Levels of secreted IFN-b protein in supernatants were measured by IFN-b ELISA. As a control, cells were mock transfected (MT) or
transfected with poly (IC) (pIC) for 24 h. (B) A549 cells and Vero cells were mock-infected or infected with Candid#1 JUNV (MOI of 1) for 24 h. Then
cells were super-infected with VEEV TC83-GFP (MOI of 0.1). At 24 h and 48 h p.i., tissue culture supernatants were harvested and virus titers were
determined by plaque assay in BHK cells. (C) Vero and A549 cells were mock-infected or infected with Candid#1 JUNV for 24 h followed by super-
infection with VEEV TC83-GFP for 24 h. VEEV TC83-driven GFP expression in infected cells was assessed by fluorescence microscopy. TC83-GFP: cells
mock-infected with Candid#1 JUNV and then infected with VEEV TC83-GFP virus. TC83-GFP+Candid: cells infected with Candid#1 JUNV and then
super-infected with VEEV TC83-GFP virus.
doi:10.1371/journal.pntd.0001659.g002
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induced ISG15 protein expression at similar levels, along with
similarly elevated levels of STAT1, including its phosphorylated
form, and RIG-I protein. However, STAT1 phosphorylation was
stronger in cells infected by Candid#1 JUNV than by Romero
JUNV at 48 h p.i., implying the possibility that IFN signaling may
be more robust in cells infected with the attenuated vaccine strain
Candid#1 JUNV.
Contribution of RIG-I to activation of the type I IFN
pathway in Candid#1 JUNV-infected cells
The cytoplasmic PRR RIG-I is involved in sensing many RNA
viruses and triggering the host IFN response that involves the
participation of the adaptor MAVS and downstream IRF3.
Subsequently, activated IRF3, in cooperation with NF-kB and
AP1 transcriptional factors, induces type I IFN production
[17,22]. Accordingly, we investigated whether the RIG-I/IRF3
pathway was responsible for sensing JUNV infection and
consequently for induction of type I IFN. For this purpose, we
studied the effect of siRNA-mediated knock-down of RIG-I and
IRF3 expression on Candid#1JUNV-induced activation of type I
IFN in A549 cells. A549 cells were transfected with siRNA for
RIG-I, IRF3, or non-targeting control siRNA. After 48 h, cells
were infected with Candid#1 JUNV for 24 h followed by analysis
of RNA and protein samples with qRT-PCR and Western
Blotting. The efficacy of gene knock-down at protein level was
confirmed by Western blotting (Figure 4B). The levels of
Candid#1 JUNV-induced IFN-b, ISG15, RIG-I and Mx2
mRNA expression were substantially impaired in A549 cells
transfected with siRNA for RIG-I or IRF3 (Figure 4A). This result
was further validated by Western blotting assay. In cells
transfected with control siRNA, Candid#1 JUNV infection led
to induction of ISG15 protein expression and STAT1 phosphor-
ylation as expected (Figure 4B). Similarly, the level of RIG-I
protein, an ISG product, also increased. In contrast, ISG 15
protein expression was undetectable during Candid#1 JUNV
infection in cells transfected with siRNAs to RIG-I or IRF3. In
IRF3 siRNA transfected cells, the level of RIG-I protein remained
comparable to the basal level of RIG-I in control siRNA-
transfected, mock-infected cells. RIG-I or IRF3 knock-down also
led to diminished STAT1 phosphorylation in virus-infected cells.
These data indicated that RIG-I/IRF3 pathway was required for
activation of type I IFN pathway in response to Candid#1 JUNV
infection.
Figure 3. Activation of IFN pathway by both vaccine and pathogenic strains of JUNV. A549 cells were mock-infected or infected with
Candid#1 or Romero strains of JUNV (MOI of 1) for the indicated times. (A) Total RNAs were extracted. IFN-b and ISG15 mRNA levels were determined
by real-time qRT-PCR and normalized to GAPDH mRNA levels and presented as relative levels to these of mock-infected sample at day 1. Data shown
are the mean of three experiments (error bar, S.D). (B) Protein lysates were prepared and subjected to western blotting analysis to detect
phosphorylated STAT1 (p-STAT1), STAT1 (STAT1), ISG15 (ISG15), RIG-I (RIG-I) and b-actin (actin) proteins.
doi:10.1371/journal.pntd.0001659.g003
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Romero strains of JUNV to IFN treatment
Our observation that both non-pathogenic Candid#1a n d
pathogenic Romero strains of JUNV activated the type I IFN
pathway raised the question of whether IFN could substantially inhibit
the growth of these viruses. Past studies showed the insensitivity of
some arenaviruses to IFNs [43–46]. We therefore characterized the
IFN sensitivity of the Candid#1 and Romero strains of viruses. To
this purpose, we treated Vero cells with IFN-a, b or c at various
concentrations for 8 h prior to virus infection and determined virus
production at 48 h p.i.. Both Candid#1 and Romero strains were
resistant to IFN-c treatment in all conditions tested (Figure 5). Pre-
treatment with IFN-b or IFN-a at a high concentration (1000 IU/ml)
led to only minimal reduction in virus titer (less than 1-log) for both
Candid#1 and Romero strains of viruses. In control experiments,
IFN-b treatment at lower concentration (125 IU/ml) was sufficient to
inhibit VSV virus production by more than 4-log (Figure S2). We
observed similar results in Vero cells pre-treated with IFNs for 24 h
prior to virus infection (data not shown). These data indicated that
both Candid#1 and Romero strains of JUNV are surprisingly
resistant to the antiviral effects of IFNs.
Discussion
The central finding we report in this study is that infection of
human A549 cells with either non-pathogenic Candid#1o r
Figure 4. RIG-I is the sensor for IFN pathway activation. A549 cells were transfected with siRNAs targeting RIG-I or IRF3, as well as with a
nontargeting control siRNA. At 48 h post-transfection, cells were mock-infected or infected with Candid#1 JUNV at an MOI of 1. (A) Total RNAs were
extracted and levels of IFN-b, ISG 15, RIG-I and Mx2 mRNA were determined by RT-qPCR. Data were normalized to the levels of GAPDH mRNA and
shown as fold-induction relative to mock-infected cells transfected with the corresponding siRNA. Values are the mean of three experiments (error
bar, S.D). (B). In parallel, protein lysates were prepared from cells. Western blotting assays were performed to determine the protein levels of
phosphorylated STAT1 (p-STAT1), STAT1 (STAT1), ISG15 (ISG15), viral NP protein (NP), RIG-I (RIG-I), IRF3 (IRF3) and b-actin (actin).
doi:10.1371/journal.pntd.0001659.g004
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type I IFN pathway, but both strains of JUNV were resistant to the
antiviral effects of type I IFN. Consistently, it has been found that
a pathogenic strain of JUNV induced IFN-b mRNA expression in
human hematopoietic progenitor CD34
+ megakaryocytes [47].
Our finding is further in agreement with clinical reports showing
elevated levels of cytokines, including IFN-a, TNF-a, IL-6 and IL-
10, in AHF patients [14–16,26–30]. Clinical data also suggest that
high levels of IFN-a in AHF patient might be correlated to poor
prognosis [14,27], yet the role of IFN and cytokine production in
AHF pathogenesis remains to be elucidated. Interestingly,
infection by LASV often triggers only weak immune responses
and is associated with minimal noticeable pathology [1,12], which
usually does not correlate with the disease outcome, suggesting the
pathogenesis of these two HF arenaviruses, JUNV and LASV, are
quite distinct.
TLR2 has been reported to act as PRR for Candid#1G Pi n
mouse macrophages [32], but the role of TLR2 as PRR for JUNV
in human cells remains to be determined. TLR2 or TLR4 are not
expressed at detectable levels in A549 cells [48], suggesting that
different PRR sensors might be utilized in JUNV recognition in
different cell types. Accordingly, our data revealed that RIG-I was
an important host sensor of JUNV infection in A549 cells. MDA5,
another main cytoplasmic PRR, has been found crucial in host
recognition of the prototypic arenavirus LCMV [49]. Further
studies would be required to clarify the role of MDA5 in JUNV
infection.
Infection with the pathogenic Romero strain of JUNV has been
reported not to induce measurable levels of IFN-b, IFN-a, TNF-a,
IL-10 or IL12, in primary human monocytes and macrophages
[31]. This observation is in contrast to data reported here and in
clinical reports. It is possible that this discrepancy is due to cell
type differences or the relatively low levels of virus growth in
human macrophages [31]. Interestingly, in agreement with our
findings in A549 and Vero cells, cytokines had no direct inhibitory
effect on Romero JUNV growth in macrophages [31].
The activation of the RIG-I/IRF3 pathway in JUNV-infected
cells is supported collectively by transcriptional changes, type I
IFN production, ISG expression, IRF3 nuclear translocation and
STAT-1 phosphorylation in this study. These findings initially
appear to be in conflict with previous observations documenting
that NPs of many arenaviruses, including NP derived from JUNV,
are capable of interfering with type I IFN induction [33–35,49]
through interaction with RIG-I and MDA5 [49] and/or inhibition
of the nuclear translocation and transcriptional activity of IRF3
[33–35]. In addition, the Z protein of New World arenaviruses,
has been reported to interact with RIG-I and inhibit its function
[50]. It has been also proposed that arenaviruses are able to evade
RIG-I recognition by virtue of the 59ppp-nucleotide overhang at
the double stranded RNA structures formed via terminal sequence
complementarity of arenavirus genomic and antigenomic RNAs
[51,52]. However, these studies, mostly based on plasmid-based
over-expression systems or in vitro biochemical analyses, do not
directly study the IFN response in JUNV–infected cells. It is worth
noting that, in cell-based reporter assay systems, over-expression of
JUNV NP indeed was not able to completely abolish the activation
of the RIG-I/IRF3 pathway in response to subsequent Sendai
virus infection [34], which implies the occurrence of leaky
activation of RIG-I/IRF3 pathway in these studies. Therefore, it
is plausible that during the early stages of JUNV infection, low
levels of NP protein might not be sufficient to completely
circumvent the activation of the RIG-I/IRF3 pathway and
induction of type I IFN response. Increased levels of NP at later
times during infection may efficiently inhibit the RIG-I/IRF3
pathway, thus enabling virus to down-regulate the type I IFN
response.
Our results demonstrate that both the non-pathogenic
Candid#1 and pathogenic Romero strains of JUNV are capable
of activating the type I IFN pathway in human A549 cells.
However, higher levels of IFN-b and ISG15 mRNAs (Figure 3A),
as well as increased levels of STAT1 phosphorylation (Figure 3B)
were identified in Candid#1 JUNV-infected cell than in Romero
JUNV-infected cells. These findings would suggest that the
attenuated Candid#1 strain might be recognized more efficiently
by RIG-I/IRF3 than Romero strain, or that Romero strain may
be more effective in counteracting the induction of type I IFN. It is
possible that sequence variation between two virus strains might
determine these subtly different host responses. Future studies are
required to identify whether the difference in type I IFN pathway
response between non-pathogenic and pathogenic strains of JUNV
has any implication in viral pathogenicity and attenuation.
Notably, both Candid#1 and Romero strains of JUNV were
only modestly sensitive to the antiviral effects of IFN pretreatment,
yet Candid#1 JUNV-infected A549 cells still established an
efficient antiviral state against another IFN-sensitive RNA virus. In
Figure 5. Sensitivity of JUNV to IFN pretreatment. Vero cells were
treated with IFN-a, b or c at the indicated concentrations for 8 h and
then infected with Romero JUNV (A) or Candid#1 JUNV (B) at an MOI of
0.1. At 2 days p.i., supernatants were collected and assayed for virus
production by plaque assay. Due to the severe cytotoxicity caused by
IFN-c treatment at 2000 U/ml, virus infection was not performed at this
condition. Data represent the average of three replicates 6SEM.
doi:10.1371/journal.pntd.0001659.g005
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might decline over the time. The slowly growing JUNV might
benefit from abated IFN effect and eventually replicate more
efficiently later. Our data are in agreement with previous studies
showing the resistance of some arenaviruses to IFNs [43,44,46].
Although the pathogenicity of many viruses may be associated
with their sensitivity to IFN [53,54], attenuation of Candid#1
vaccine strain is unlikely due to enhanced sensitivity to IFN.
In conclusion, we have shown that both the non-pathogenic
Candid#1 and pathogenic Romero strains of JUNV induced a
RIG-I dependent type I IFN response in infected cells, but both
Candid#1 and Romero strains of viruses were insensitive to the
antiviral effects of IFN despite the fact that Candid#1 JUNV-
infected cells mounted an effective antiviral state against another
IFN-sensitive RNA virus. Future studies are warranted to
investigate the importance of type I IFN signaling pathway in
AHF pathogenesis in animal models. Gaining insights into JUNV
pathogenesis will potentially enable us to design antiviral
therapeutics to modulate the host antiviral response, limit infection
and improve the disease outcome.
Supporting Information
Figure S1 IRF3 nuclear translocation in poly(IC)-trans-
fected A549 cells. A549 cells were transfected with poly (IC) by
electroporation. At 0 hr and 1 hr after treatment, cytoplasmic
extract (Cyto) and nuclear extract (Nu) were prepared to measure
the IRF3 protein level in cytoplasm and nuclear fractions by SID-
SRM analysis.
(TIF)
Figure S2 Sensitivity of VSV to IFN pretreatment. Vero
cells were treated with IFN-a, b or c at the indicated
concentrations for 8 h and then infected with VSV at an MOI
of 0.1. At 12 h p.i., supernatants were collected and assayed for
virus production by plaque assay. Data represent the average of
three replicates 6SEM.
(TIF)
Text S1 Methods for quantitative proteomic analysis
(LC-SRM-MS analysis).
(DOC)
Table S1 SRM parameters of SRM assays of IRF3.
Masses listed are for the natural forms of the peptides.
(DOC)
Author Contributions
Conceived and designed the experiments: CH OAK SP. Performed the
experiments: CH OAK NEY AVS ALP AGW YZ BT. Analyzed the data:
CH OAK ARB SP. Contributed reagents/materials/analysis tools: YZ
BT. Wrote the paper: CH OAK ARB JCDLT SP.
References
1. Buchmeier MJ, de la Torre J-C, Peters CJ (2007) 51. Arenaviridae: The Viruses
and Their Replication. In: Knipe DM, ed. Fields’ Virology. Philadelphia:
Lippincott, Williams and Wilkins. pp 1635–1668.
2. Tortorici MA, Albarino CG, Posik DM, Ghiringhelli PD, Lozano ME, et al.
(2001) Arenavirus nucleocapsid protein displays a transcriptional antitermina-
tion activity in vivo. Virus Res 73: 41–55.
3. Meyer BJ, Southern PJ (1994) Sequence heterogeneity in the termini of
lymphocytic choriomeningitis virus genomic and antigenomic RNAs. J Virol 68:
7659–7664.
4. Beyer WR, Popplau D, Garten W, von Laer D, Lenz O (2003) Endoproteolytic
processing of the lymphocytic choriomeningitis virus glycoprotein by the
subtilase SKI-1/S1P. J Virol 77: 2866–2872.
5. Lenz O, ter Meulen J, Klenk HD, Seidah NG, Garten W (2001) The Lassa virus
glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/
S1P. Proc Natl Acad Sci U S A 98: 12701–12705.
6. Pinschewer DD, Perez M, Sanchez AB, de la Torre JC (2003) Recombinant
lymphocytic choriomeningitis virus expressing vesicular stomatitis virus
glycoprotein. Proc Natl Acad Sci U S A 100: 7895–7900.
7. Poch O, Sauvaget I, Delarue M, Tordo N (1989) Identification of four conserved
motifs among the RNA-dependent polymerase encoding elements. EMBO J 8:
3867–3874.
8. Perez M, Craven RC, de la Torre JC (2003) The small RING finger protein Z
drives arenavirus budding: implications for antiviral strategies. Proc Natl Acad
Sci U S A 100: 12978–12983.
9. Strecker T, Eichler R, Meulen J, Weissenhorn W, Dieter Klenk H, et al. (2003)
Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like
particles [corrected]. J Virol 77: 10700–10705.
10. Urata S, Noda T, Kawaoka Y, Yokosawa H, Yasuda J (2006) Cellular factors
required for Lassa virus budding. J Virol 80: 4191–4195.
11. Peters CJ (2002) Human infection with arenaviruses in the Americas. Curr Top
Microbiol Immunol 262: 65–74.
12. McCormick JB, Fisher-Hoch SP (2002) Lassa fever. Curr Top Microbiol
Immunol 262: 75–109.
13. Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: progress and
challenges. Nat Med 10: S110–121.
14. Levis SC, Saavedra MC, Ceccoli C, Feuillade MR, Enria DA, et al. (1985)
Correlation between endogenous interferon and the clinical evolution of patients
with Argentine hemorrhagic fever. J Interferon Res 5: 383–389.
15. Maiztegui JI (1975) Clinical and epidemiological patterns of Argentine
haemorrhagic fever. Bull World Health Organ 52: 567–575.
16. Enria DA, Briggiler AM, Sanchez Z (2008) Treatment of Argentine
hemorrhagic fever. Antiviral Res 78: 132–139.
17. Versteeg GA, Garcia-Sastre A (2010) Viral tricks to grid-lock the type I
interferon system. Curr Opin Microbiol 13: 508–516.
18. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. (2007)
Interferons at age 50: past, current and future impact on biomedicine. Nat Rev
Drug Discov 6: 975–990.
19. Bowie AG, Unterholzner L (2008) Viral evasion and subversion of pattern-
recognition receptor signalling. Nat Rev Immunol 8: 911–922.
20. Kawai T, Akira S (2008) Toll-like receptor and RIG-I-like receptor signaling.
Ann N Y Acad Sci 1143: 1–20.
21. Barbalat R, Lau L, Locksley RM, Barton GM (2009) Toll-like receptor 2 on
inflammatory monocytes induces type I interferon in response to viral but not
bacterial ligands. Nat Immunol 10: 1200–1207.
22. Barral PM, Sarkar D, Su ZZ, Barber GN, DeSalle R, et al. (2009) Functions of
the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate
immunity. Pharmacol Ther 124: 219–234.
23. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006)
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA
viruses. Nature 441: 101–105.
24. Baum A, Sachidanandam R, Garcia-Sastre A (2010) Preference of RIG-I for
short viral RNA molecules in infected cells revealed by next-generation
sequencing. Proc Natl Acad Sci U S A 107: 16303–16308.
25. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A
diverse range of gene products are effectors of the type I interferon antiviral
response. Nature 472: 481–485.
26. Ferbus D, Saavedra MC, Levis S, Maiztegui J, Falcoff R (1988) Relation of
endogenous interferon and high levels of 29-59 oligoadenylate synthetase in
leukocytes from patients with Argentine hemorrhagic fever. J Infect Dis 157:
1061–1064.
27. Levis SC, Saavedra MC, Ceccoli C, Falcoff E, Feuillade MR, et al. (1984)
Endogenous interferon in Argentine hemorrhagic fever. J Infect Dis 149:
428–433.
28. Heller MV, Saavedra MC, Falcoff R, Maiztegui JI, Molinas FC (1992) Increased
tumor necrosis factor-alpha levels in Argentine hemorrhagic fever. J Infect Dis
166: 1203–1204.
29. Marta RF, Montero VS, Hack CE, Sturk A, Maiztegui JI, et al. (1999)
Proinflammatory cytokines and elastase-alpha-1-antitrypsin in Argentine
hemorrhagic fever. Am J Trop Med Hyg 60: 85–89.
30. Marta RF, Montero VS, Molinas FC (1998) Systemic disorders in Argentine
haemorrhagic fever. Bulletin De L Institut Pasteur 96: 115–124.
31. Groseth A, Hoenen T, Weber M, Wolff S, Herwig A, et al. (2011) Tacaribe virus
but not junin virus infection induces cytokine release from primary human
monocytes and macrophages. PLoS Negl Trop Dis 5: e1137.
32. Cuevas CD, Lavanya M, Wang E, Ross SR (2011) Junin virus infects mouse cells
and induces innate immune responses. J Virol 85: 11058–11068.
33. Martinez-Sobrido L, Emonet S, Giannakas P, Cubitt B, Garcia-Sastre A, et al.
(2009) Identification of amino acid residues critical for the anti-interferon activity
of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis
virus. J Virol 83: 11330–11340.
34. Martinez-Sobrido L, Giannakas P, Cubitt B, Garcia-Sastre A, de la Torre JC
(2007) Differential inhibition of type I interferon induction by arenavirus
nucleoproteins. J Virol 81: 12696–12703.
Activation of IFN Pathway by Junı ´n Virus
www.plosntds.org 9 May 2012 | Volume 6 | Issue 5 | e165935. Martinez-Sobrido L, Zuniga EI, Rosario D, Garcia-Sastre A, de la Torre JC
(2006) Inhibition of the type I interferon response by the nucleoprotein of the
prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 80:
9192–9199.
36. Kolokoltsova OA, Yun NE, Poussard AL, Smith JK, Smith JN, et al. (2010)
Mice Lacking Alpha/Beta and Gamma Interferon Receptors Are Susceptible to
Junin Virus Infection. J Virol 84: 13063–13067.
37. Yun NE, Linde NS, Dziuba N, Zacks MA, Smith JN, et al. (2008) Pathogenesis
of XJ and Romero strains of Junin virus in two strains of guinea pigs. Am J Trop
Med Hyg 79: 275–282.
38. Forbus J, Spratt H, Wiktorowicz J, Wu Z, Boldogh I, et al. (2006) Functional
analysis of the nuclear proteome of human A549 alveolar epithelial cells by
HPLC-high resolution 2-D gel electrophoresis. Proteomics 6: 2656–2672.
39. Fusaro VA, Mani DR, Mesirov JP, Carr SA (2009) Prediction of high-
responding peptides for targeted protein assays by mass spectrometry. Nat
Biotechnol 27: 190–198.
40. Lange V, Picotti P, Domon B, Aebersold R (2008) Selected reaction monitoring
for quantitative proteomics: a tutorial. Mol Syst Biol 4: 222.
41. Spotts DR, Reich RM, Kalkhan MA, Kinney RM, Roehrig JT (1998)
Resistance to alpha/beta interferons correlates with the epizootic and virulence
potential of Venezuelan equine encephalitis viruses and is determined by the 59
noncoding region and glycoproteins. J Virol 72: 10286–10291.
42. Paessler S, Ni H, Petrakova O, Fayzulin RZ, Yun N, et al. (2006) Replication
and clearance of Venezuelan equine encephalitis virus from the brains of
animals vaccinated with chimeric SIN/VEE viruses. J Virol 80: 2784–2796.
43. Asper M, Sternsdorf T, Hass M, Drosten C, Rhode A, et al. (2004) Inhibition of
different Lassa virus strains by alpha and gamma interferons and comparison
with a less pathogenic arenavirus. J Virol 78: 3162–3169.
44. Lucia HL, Coppenhaver DH, Baron S (1989) Arenavirus infection in the guinea
pig model: antiviral therapy with recombinant interferon-alpha, the immuno-
modulator CL246,738 and ribavirin. Antiviral Res 12: 279–292.
45. Stephen EL, Scott SK, Eddy GA, Levy HB (1977) Effect of interferon on
togavirus and arenavirus infections of animals. Tex Rep Biol Med 35: 449–454.
46. Peters CJ, Liu CT, Anderson GW, Jr., Morrill JC, Jahrling PB (1989)
Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever
contrasted. Rev Infect Dis 11 Suppl 4: S743–749.
47. Pozner RG, Ure AE, Jaquenod de Giusti C, D’Atri LP, Italiano JE, et al. (2010)
Junin virus infection of human hematopoietic progenitors impairs in vitro
proplatelet formation and platelet release via a bystander effect involving type I
IFN signaling. PLoS Pathog 6: e1000847.
48. Zhang Z, Liu R, Noordhoek JA, Kauffman HF (2005) Interaction of airway
epithelial cells (A549) with spores and mycelium of Aspergillus fumigatus. J Infect
51: 375–382.
49. Zhou S, Cerny AM, Zacharia A, Fitzgerald KA, Kurt-Jones EA, et al. (2010)
Induction and inhibition of type I interferon responses by distinct components of
lymphocytic choriomeningitis virus. J Virol 84: 9452–9462.
50. Fan L, Briese T, Lipkin WI (2010) Z proteins of New World arenaviruses bind
RIG-I and interfere with type I interferon induction. J Virol 84: 1785–1791.
51. Marq JB, Hausmann S, Veillard N, Kolakofsky D, Garcin D (2011) Short
double-stranded RNAs with an overhanging 59 ppp-nucleotide, as found in
arenavirus genomes, act as RIG-I decoys. J Biol Chem 286: 6108–6116.
52. Marq JB, Kolakofsky D, Garcin D (2010) Unpaired 59 ppp-nucleotides, as found
in arenavirus double-stranded RNA panhandles, are not recognized by RIG-I.
J Biol Chem 285: 18208–18216.
53. Daffis S, Lazear HM, Liu WJ, Audsley M, Engle M, et al. (2011) The naturally
attenuated Kunjin strain of West Nile virus shows enhanced sensitivity to the
host type I interferon response. J Virol 85: 5664–5668.
54. Seo SH, Hoffmann E, Webster RG (2002) Lethal H5N1 influenza viruses escape
host anti-viral cytokine responses. Nat Med 8: 950–954.
Activation of IFN Pathway by Junı ´n Virus
www.plosntds.org 10 May 2012 | Volume 6 | Issue 5 | e1659